Eptifibatide
- Generic Name
- Eptifibatide
- Brand Names
- Integrilin, Eptifibatide Accord
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 188627-80-7
- Unique Ingredient Identifier
- NA8320J834
- Background
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
- Indication
For treatment of myocardial infarction and acute coronary syndrome.
- Associated Conditions
- Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI)
- Associated Therapies
- -
Multi-arm Optimization of Stroke Thrombolysis
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 514
- Registration Number
- NCT03735979
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
- Conditions
- Angina, UnstableAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 100
- Registration Number
- NCT02925923
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Arthur Pancioli
- Target Recruit Count
- 27
- Registration Number
- NCT01977456
- Locations
- 🇺🇸
St. Elizabeth Healthcare System Edgewood, Edgewood, Kentucky, United States
🇺🇸St. Elizabeth Healthcare Florence, Florence, Kentucky, United States
🇺🇸St. Elizabeth Healthcare Ft. Thomas, Ft. Thomas, Kentucky, United States
Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 70
- Registration Number
- NCT01919723
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
- Conditions
- Non ST Elevation Myocardial Infarction
- Interventions
- Drug: PlaceboDrug: Eptifibatide
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 140
- Registration Number
- NCT01863134
- Locations
- 🇵🇱
Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland
🇵🇱Department of Internal Medicine and Clinical Pharmacology, Katowice, Poland
🇵🇱Division of Molecular Biology and Clinical Genetics, Jagiellonian University Medical College, Krakow, Poland
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
- Conditions
- Myocardial InfarctionAcute Coronary SyndromesUnstable Angina
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Medicure
- Target Recruit Count
- 535
- Registration Number
- NCT01522417
- Locations
- 🇺🇸
Doylestown Hospital, Doylestown, Pennsylvania, United States
🇺🇸Redmond Regional Medical Center, Rome, Georgia, United States
🇺🇸Osceola Regional Medical Center, Kissimmee, Florida, United States
The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 91
- Registration Number
- NCT01454440
- Locations
- 🇮🇹
University of Turin, Turin, TO, Italy
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: OtamixabanDrug: Placebo (for Otamixaban)Drug: Placebo (for UFH)Drug: UFHDrug: Placebo (for Eptifibatide)Drug: Eptifibatide
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13220
- Registration Number
- NCT01076764
- Locations
- 🇺🇸
Investigational Site Number 840911, Pittsburgh, Pennsylvania, United States
🇦🇷Investigational Site Number 032010, Cordoba, Argentina
🇦🇷Investigational Site Number 032020, Mendoza, Argentina
Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2009-07-24
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00945308
- Locations
- 🇮🇱
Assaf Harofeh Medical Center, Beer Yakov, Israel
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
- Conditions
- StrokeIschemic StrokeBrain Infarction
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 126
- Registration Number
- NCT00894803
- Locations
- 🇺🇸
West Virginia University Hospital, Morgantown, West Virginia, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center Santa Monica, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.